Ken is currently the Vice Chairman of StemCyte, International Inc. as well as a Board member of StemCyte Taiwan and the StemCyte India JV.StemCyte provides lifesaving therapy UCB product to the world’s leading hospitals and Transplant centers for patients that cannot find a viable bone marrow match. StemCyte has operations in the USA, Taiwan and India as well as research collaborations with a number of leading researcher and research institutions in and outside the US. He has held numerous positions within StemCyte since his retirement from Johnson & Johnson in April 2003.
Ken had an outstanding and diverse career with Johnson & Johnson that spanned almost 26 years. His last assignment was Senior Vice President of Independence Technology, L.L.C., a Johnson & Johnson Company, which he started, that is dedicated to providing innovative products to people with disabilities and was responsible for all aspects of managing new business opportunities worldwide, a key element in building a global franchise within Johnson & Johnson. He held this position from 2000 to his 2003. From 1995 to 2000 he was General Manager of Independence Technology and served as a member of the Global Management Board throughout.
Ken served Johnson & Johnson in a series of assignments from 1974 to 1991. Beginning in Engineering and Operations with the Domestic Operating Company, he subsequently moved to the Johnson & Johnson Baby Products Company. There he progressed through responsibilities in Operations, Marketing and Business Development and served on the Management Board of the Baby Products Company. With the formation of Consumer Products, Inc. in 1990, he was also appointed to their Management Board as Vice President, Business Development.
From 1991 until his return to J&J in 1995, Ken was a Corporate Officer and Vice President, Worldwide Business Development for the Church & Dwight Company. He was responsible for developing brand value and business for the Arm & Hammer Brand on a global basis. In 1994, he added research and development responsibilities as Vice President, Business Development and Technology.
Prior to joining Johnson & Johnson, Ken served with the United States Navy as a carrier pilot and remained actively involved in aviation and non aviation command assignments with the Naval Reserve until his retirement in 1999 with the rank of Captain. He holds a Bachelors of Science, Masters of Science and an MBA, all from Rutgers University.
Ken also serves or served on a number of Boards and Advisory Panels. To name a few:
Board member of Cerebral Palsy of New Jersey
Advisory Board of the Human Engineering Research Laboratory of the University of Pittsburgh.
Advisory Board of the National Institute for Child Health and Development (NIH)
1968 - BS, Rutgers University, New Brunswick, NJ
1973 - MS, Rutgers University, New Brunswick, NJ (Returned for Graduate studies after completing active military service)
- MBA Finance – Rutgers Graduate School of Business, Newark, NJ
1968 – 1972 Active Military Duty - US Navy, Officer, Carrier Pilot, (Served over 30 years Active Duty plus Reserve Duty)
1972 – 1999 US NAVY Officer, Carrier Pilot (Reserve Duty)
1973 – 1974 Research Scientist - Bristol-Myers Products
1974 – 1976 Senior Engineer – Johnson & Johnson Domestic Operating Co
1976 – 1978 Manager, Package Engineering – Johnson & Johnson Baby Products Co
1978 – 1980 Purchasing Manager – Johnson & Johnson Baby Products Co
1980 – 1983 Director of Operations – Johnson & Johnson Baby Products Co.
1983 – 1986 Director of Licensing – Johnson & Johnson Baby Products Co.
1986 – 1989 Vice President, New Business Development, and Member of the Board – Johnson & Johnson Baby Products Co
1989 – 1991 Vice President, Business Development, and Member of the Board– Johnson & Johnson Consumer Products Inc.
1991 – 1993 Vice President, New Business Development Church & Dwight Company
1991 – 1995
Corporate Vice President, Member of the Executive Committee Church & Dwight
Company, Inc. ( Head of R&D, International and Business Development) Led
three (3) significant areas of responsibility and growth.Vice President,
Worldwide New Business Development, Vice President International and Vice
President, Research & Development.Responsible for 120 individuals. Reported to Chairman and CEO
1995 – 1999 General Manager Johnson & Johnson Exploratory Products, Inc (Created and led a new J&J company)
back to Johnson & Johnson by senior J&J executives. Led all aspects of an internal start-up
including which concluded with a US FDA approved Class III medical device. Led
company in: design, development, manufacture, marketing, selling distribution,
FDA clinical and non-clinical testing (Class III Device), reimbursement, after
sales service and internet strategy for a transformational product for people
1999 – 2003 Senior Vice President Johnson & Johnson Independence Technology Inc. (Responsible for all Mergers and Acquisitions, International Business and new products)
After leading the effort to create Johnson &
Johnson’s newest franchise and
platform for growth providing products and services for people with
disabilities, was tasked with developing a global strategy as well as develop
and execute a strategic plan that expands Independence Technology from a
one-product company to a viable global franchise. Member of Global Franchise Committee and
2003 – 2012 - Chairman and CEO, StemCyte, Inc. - Member of the Board of StemCyte, Inc., StemCyte Taiwan and StemCyte India Therapeutics Ltd. (Headed all aspects of this stem cell therapeutics company)
Upon retirement from Johnson & Johnson after a distinguished 25+ year career, was recruited to become the CEO of StemCyte, Inc. one of the world’s largest umbilical cord blood banks providing life saving therapy for individuals who are suffering from numerous forms of leukemia and other disorders.. Since joining StemCyte in April 2003 has launched two new businesses in the USA and Taiwan, increased revenue by over 10 fold and has entered into strategic agreements with leading researchers to investigate and develop the potential regenerative medical applications of stem cells sourced from umbilical cord blood. Established StemCyte India Therapeutics Ltd. as a Joint Venture with the leading healthcare provider in India (Apollo Hospital Group and the largest privately held pharmaceutical company (Cadila company in the world and has initiated plans to expand into several other strategic areas.
2012 – Present - Vice Chairman and Chief Business and Strategy Officer, StemCyte International
Responsible for developing the strategic direction of the Company which includes new indications for umbilical cord blood stem cells, new technologies. Responsible for leading StemCyte’s partnership with Prof Wise Young and Prof John Lin to investigate the potential benefits of UCB cells to treat Chronic Spinal Cord injury and Chronic Stroke. Phase II clinical studies have been completed in Hong Kong and Kunming China and are progressing toward follow-on Phase II trials in the USA and India.
2012 – Present – Chairman StemCyte India Therapeutics Ltd Joint Venture
Created and executed this Joint Venture company in 2008 with the company commencing operations in 2010. The Joint Venture company has become the leading provider of UCB transplant units in India and has maintained a cash flow positive position since 2012. The CEO of StemCyte India reports to me.
2015 – Present – CEO Mononuclear Therapeutics Ltd.
Prof. Wise Young, PhD, MD and I formed Mononuclear Therapeutics in 2015 in order to take our knowledge of the stem cell field to the next level by creating a company that is more operationally and economically efficient and takes advantage of several exciting complimentary and protected technologies that will result in more rapid translational applications of UCB cells to treat a number of currently untreatable disorders in a cost effective way.